Effects of the administration of B663 [G 30 320, Lamprene, clofazimine (Geigy)] on three groups of lepromatous and borderline of leprosy.
D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002648:Child; D002991:Clofazimine / Q000009:adverse effects / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004893:Erythema Nodosum / Q000188:drug therapy; D005260:Female; D006801:Humans; D007916:Lepromin; D007918:Leprosy / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000187:drug effects / Q000302:isolation & purification; D010859:Pigmentation Disorders / Q000139:chemically induced; D012008:Recurrence
D007916:Lepromin; D003622:Dapsone; D002991:Clofazimine